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Abstract 
Thyroid disease and diabetes mellitus (DM) are the most common endocrinopathies in clinical practice that interact with each other. On 
the one hand, thyroid hormones regulate carbohydrate metabolism and pancreas functions, and on the other hand DM affects the func-
tion and work of the thyroid gland. Diabetic retinopathy (DR) is a highly specific neurovascular complication of both type 1 and type 2 
DM, which is a significant cause of vision loss on a global scale. In DM, the internal blood-retinal barrier is the earliest to be damaged, and 
changes in neuroretina result from the loss of its adaptation to metabolic disorders. Patients with DM have a higher incidence of thyroid 
disease compared to people without DM. The coexistence of DM with thyroid disease leads to endothelial damage, and the degree of its 
dysfunction has a significant impact on the course of macro- and microangiopathic complications in patients. There are few reports in 
the literature about the impact of thyroid disease and substitution of levothyroxine preparations on the development and course of DR 
in patients with DM. It is unknown whether the fact that patients with unrecognised hypothyroidism are not treated with levothyroxine 
preparations disrupts thyroid hormone homeostasis to the extent that it may contribute to a higher incidence of DR. This review discusses 
recent clinical trials for thyroid dysfunction in patients with DR. (Endokrynol Pol 2020; 71 (1): 176–183)
Key words: thyroid disease; diabetes mellitus; diabetic retinopathy
Introduction 
Thyroid disease and diabetes mellitus (DM) are the 
two most common endocrinopathies [1, 2]. Thyroid 
hormones regulate basic life processes centrally and 
peripherally [3, 4]. The connection between DM and 
thyroid disorders is characterised by a complex interac-
tion. Undiagnosed thyroid dysfunction can negatively 
affect DM and its complications [5]. Microvascular com-
plications of DM (retinopathy, nephropathy, and neu-
ropathy) are increasingly important causes of morbidity 
and mortality, and care for affected patients contributes 
to burgeoning healthcare costs [6]. Diabetic retinopathy 
(DR) is a highly specific neurovascular complication of 
both type 1 and type 2 DM, which is a significant cause 
of vision loss on a global scale [7, 8]. The increased 
risk of blindness among DM patients is a huge clinical 
problem. There are only a few reports in the literature 
in which the effects of thyroid disease, including au-
toimmune thyroid diseases (AITD) and substitution of 
levothyroxine preparations, on the development and 
occurrence of DR have been demonstrated. This review 
discusses recent clinical trials for thyroid dysfunction 
in patients with diabetic DR. Articles and their refer-
ences were assessed and included as deemed relevant 
by the authors.
Autoimmune thyroid disease
Autoimmunity is the body’s immune response directed 
against its own antigen or group of antigens. The emer-
gence of autoimmune diseases is influenced by the 
interaction of causative factors (environmental factors, 
including infections), inheritance of sensitising genes, 
autoantigens, intrinsic antigen tolerance disorders, 
and apoptosis mechanisms [9]. Systemic connective 
tissue diseases result in emergence of autoantibodies 
that react with antigens throughout the body. Reac-
tion with antigens specific only to a particular tissue 
causes organ-specific diseases, leading to disruption 
of physiological function and/or tissue damage of this 
organ [9, 10]. The dynamics of an autoimmune disease 
is determined by antibody titres and the intensity of 
autoreactive T lymphocyte responses [11]. Autoim-
mune diseases are characterised by a chronic course 
with periods of exacerbation and remission, and het-
erogeneity in terms of incidence, clinical symptoms, 
and their pathogenesis. Their incidence is constantly 
increasing, currently constituting about 5% of the 
global population, placing third in highly developed 
countries regarding the number of cases and mortality 
resulting directly and indirectly from these diseases 
(after cancer and cardiovascular diseases) [12, 13]. In 
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tion of blood-retina barriers (BRB), which prevent the 
penetration of antigens and macromolecules from 
the choroid to the retinal space, the layer consisting 
mainly of photoreceptors [25]. In DM, the internal 
BRB, consisting mainly of vascular endothelial cells, 
pericytes, and glial cells and forming a functional reti-
nal neurovascular unit, is the earliest to be damaged 
[23, 24]. Changes in neuroretina result from the loss 
of its adaptation to metabolic disorders accompanying 
DM [26]. Retinal neurodegeneration may overtake the 
microvascular changes characteristic of DR and play 
a role in its pathogenesis, but not in all diabetics [27]. 
Factors influencing the development of diabetic 
retinopathy are presented in Figure 1 [28].
Molecular mechanisms affecting retinal microcir-
culation disorders leading to BRB breakdown include 
inflammatory infiltrate, loss of pericytes, the kinin–kal-
likrein system, and vascular endothelial growth (VEGF) 
[28]. Vascular endothelial growth factor is the main 
factor regulating angiogenesis, stimulating proliferation 
and increasing the permeability of endothelial cells of 
veins, arteries, and lymphatic vessels. In 1994, Adamis 
et al. found increased expression of VEGF in ocular 
tissues in people with DR, and since then numerous 
studies have been conducted and published on the role 
of VEGF in diabetes-related diseases. It has been indi-
cated that VEGF is responsible for neovascularisation 
and damage caused by excessive vascular permeability 
[29]. Risk factors for the development and progression 
of DR are, among others: duration of diabetes, meta-
bolic imbalance of diabetes, hypertension, and lipid 
disorders [30]. The classic symptoms of DR include 
microaneurysms, haemorrhage, hard exudate (lipid 
clusters), cotton wool spots (due to retinal ischaemia), 
venous dilatation and beading, and intraretinal vascular 
abnormalities [31]. These symptoms can be assigned to 
two DR phases: non-proliferative diabetic retinopathy 
(NPDR) constituting the early phase of DR, and pro-
liferative diabetic retinopathy (PDR), which is a severe 
degree of DR with an angiogenic response of the retina 
to its extensive ischaemia and capillary occlusion (with 
neovascularisation or/and intravitreal/epiretinal bleed-
ing) [32, 33]. 
Treatment of diabetic retinopathy
The main and most important treatment of DR is to im-
prove the metabolic control of diabetes, normalise blood 
lipids, and achieve recommended blood pressure [34]. 
Many studies on different populations demonstrated 
a significant increase in the prevalence of DR with in-
creasing glycated haemoglobin (HbA1c) levels [35–37]. 
Patients with DM1 who underwent intensive insulin 
therapy demonstrated that the risk of developing DR 
women, autoimmune diseases occur more often than 
in men, constituting ~78%, which may indicate the 
participation of sex hormones in their development [14]. 
There are more than 80 disease entities known whose 
peak incidence falls between the age of 40 and 50 years 
[12]. The thyroid gland is the organ in which autoim-
mune diseases develop most often [15]. Organ-specific 
autoimmune thyroid diseases (AITD) include Graves’ 
disease (GD) and chronic lymphocytic (autoimmune) 
thyroiditis, or Hashimoto’s thyroiditis (HT). Active 
CD4 lymphocytes, co-stimulating B lymphocytes for 
the production of anti-thyroid antibodies, participate 
in their pathogenesis. In HT, cytotoxic T cells destroy 
thyrocytes leading to hypothyroidism. In GD, active 
B lymphocytes produce antibodies that stimulate the 
thyroid-stimulating hormone receptor (TSHR) causing 
overproduction of thyroid hormones and hyperthy-
roidism [16]. The following thyroid hormone levels are 
used to monitor thyroid function and disease develop-
ment: free thyroxine (fT4), free triiodothyronine (fT3), 
and pituitary hormone — thyroid-stimulating hormone 
(TSH); as well as titres of antithyroglobulin antibodies 
(ATA), including antithyroid peroxidase antibodies 
(aTPO), antithyroglobulin antibodies (aTG), and TSH 
receptor autoantibodies (anti-TSHR, TRAb) [17]. Hashi-
moto’s thyroiditis is both the most common endocrine 
disease and the most common non-pathogenic cause of 
hypothyroidism [15, 18]. HT is diagnosed on the basis 
of imaging and laboratory tests: ultrasounds of hy-
poechoic thyroid parenchyma, increased aTPO and/or 
aTG antibody titres, and increased TSH concentration. 
The ATPO antibody titre correlates with the number of 
autoreactive lymphocytes infiltrating the thyroid gland 
and the degree of its damage [19].
Diabetic retinopathy
Diabetic eye disease is a common term for vascular-re-
lated changes and all other types of eye complications 
caused by DM [7]. It is a highly specific neurovascular 
complication of both type 1 and type 2 DM. DR is a sig-
nificant cause of vision loss on a global scale. In 2015, 
415 million DR cases were diagnosed globally, and it 
is estimated that this number will increase to 642 mil-
lion in 2040 [7, 8]. Neurovascular changes in the form 
of neurodegeneration were first discovered in 1960 in 
post-mortem examinations of patients with DM. The 
discovery of neurovascular changes in the retina in DM 
patients began the era of research on damage to the 
neural part of the retina [20–22]. The retina is a neural 
tissue 90% of which consists of neurons and glial cells 
(astrocytes and Müller cells) [23, 24]. Retinal pigment 
epithelium (RPE) together with Bruch’s membrane 
(the inner part of the choroid) are involved in forma-
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was reduced by 76%, and its progression was slowed 
by 54% [38]. In DM2 patients it was shown that the 
beneficial effect of intensive treatment reducing HbA1c 
by 1% led to the reduction of DR progression by 21%, 
and to a 30% reduction of the need for laser therapy. In 
the same study reducing systolic pressure by 10 mmHg 
reduced the risk of microangiopathy, including DR, by 
13% [39, 40]. They showed that it was not the particular 
anti-diabetic drug used, i.e. sulfonylurea or metformin 
or insulin, but the degree of glycaemic control that 
mattered for prevention of DR [39]. Intensive insulin 
therapy is a beneficial method of prevention of DR 
because it helps achieve good glycaemic control and 
improves retinal blood flow and the vascular tone of 
retinal microvasculature [41]. Joint conclusions from 
various studies, depending on the type of diabetes, 
agree that intensive glycaemic control from the time 
of diagnosis of diabetes is beneficial in preventing 
the onset of DR and in delaying its progression, and 
an HbA1c level of < 7% is recommended [34]. Laser 
retinal photocoagulation is a recognised treatment 
method for DR. It is used to destroy areas of ischaemia 
in the retina and hard exudates [42]. Many randomised 
control trials demonstrated the benefit of panretinal 
photocoagulation (PRP) and focal/grid macular laser 
therapy [43]. The standard treatment in PDR is PRP, 
which is effective but has established side effects such 
as peripheral visual-field constraints [44]. Surgical treat-
ment in the course of ophthalmological complications 
is represented mainly by vitrectomy [45]. Drugs target-
ing VEGF (anti-VEGF) have been studied extensively 
in diabetic macular oedema (DMO), and results have 
shown regression of DR with anti-VEGF treatment 
[46]. Recent studies have shown that anti-VEGF is not 
inferior to PRP for PDR while treatment is maintained, 
although the recurrence rate when anti-VEGF treatment 
is stopped is unclear [44]. In vitreous haemorrhage, 
where PRP cannot be performed, use of anti-VEGF 
medications can treat underlying PDR and delay or 
reduce the need for vitrectomy. However, anti-VEGF 
treatment requires careful patient selection and moni-
toring [44].
Thyroid dysfunction in patients 
with diabetes
Thyroid disease and DM are the two most common en-
docrinopathies occurring in clinical practice [1, 2]. DM 
and thyroid dysfunction have a mutual influence: on 
the one hand, thyroid hormones regulate carbohydrate 
metabolism and pancreas functions, and on the other 
hand, DM affects thyroid gland function and work [47]. 
Common pathophysiological connections of thyroid 
disease and DM are indicated by an increasing number 
of studies on their biochemical, genetic, and hormonal 
interactions. It was first stated in the NHANES III study 
that thyroid disease was more common in patients with 
DM than in the non-DM population. Examining pa-
tients with DM, Perros et al. showed a general incidence 
of thyroid disease at 13.4% in this group, with women 
Diabetic
retinopathy
Advanced glycation
end products
Oxidative 
stress
Epigenetic 
changes
Inammation
PKC pathway
Polyol 
pathway
Hyperglycemia and 
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Hyperglycemia and 
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Figure 1. Factors influencing the development of diabetic retinopathy [28]. PKC — protein kinase C
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with type 1 DM (31.4%) noted most often, and men 
with type 2 DM most rarely (6.9%) [48]. Other studies 
have shown that the incidence of thyroid disease ranges 
from 4.8% to 31.4% [49, 50]. The causes that can cause 
such large differences in test results include various 
diagnostic criteria for thyroid dysfunction, a different 
degree of iodine intake between different regions, dif-
ferent sensitivity of TSH detection tests, and a large 
variety of populations tested [51]. Thyroid dysfunction 
has been found to occur more often in people with type 
1 DM compared to type 2 DM, and the incidence of 
AITD in patients with type 1 DM varies from 3 to 50% 
[52]. In addition, in patients with positive IgG antibodies 
(antibodies to glutamic acid decarboxylase, anti-GAD), 
a 3.5-fold increased risk of HT has been noted [53]. The 
most recent meta-analysis performed on all available 
data of 10,920 patients with DM showed an average 
frequency of thyroid disease of 11%, with no difference 
between type 1 DM and type 2 DM [54]. In the HUNT 
2 study it was established that autoimmune DM was 
associated with a higher age-corrected occurrence of 
hypothyroidism in both women (prevalence rate 1.79) 
and men (prevalence rate 2.71) compared to the absence 
of DM [55]. Positive aTPO was shown in 38% of people 
with DM who subsequently developed full-blown or 
subclinical hypothyroidism (SCH) [56,57,58]. Based 
on a meta-analysis, Chang et al. determined that the 
incidence of SCH in patients with type 2 DM was 
10.2%, while type 2 DM was associated with a 1.93-fold 
increase in SCH (95% CI: 1.66–2.24) [55]. Palma et al. 
showed in their study that SCH was the most common 
thyroid dysfunction observed, appearing in 11.8% of 
patients, and it was more common in this group than 
in people without DM [52]. Thyroid hormones affect 
glucose metabolism through several mechanisms, 
which are shown in Figure 2 and 3 [47]. 
In people with euthyroid disease with DM, the levels 
of triiodothyronine (T3), TSH, and thyrotropin-releas-
ing hormone (TRH) are subject to glycaemic changes 
in two major areas. Glycaemia is involved in the 
regulation of the hypothalamic-pituitary-thyroid axis 
feedback and TSH release from the hypothalamus; it 
also affects conversion of thyroxine (T4) to T3 in periph-
eral tissues. Nocturnal TSH peak and TSH response to 
TRH are impaired in DM patients [59–61]. Reduced T3 
levels that normalise with improved glycaemic control 
have been seen in patients with decompensated DM. 
Higher plasma insulin levels associated with insulin 
resistance (IR) act pro-proliferatively on the thyroid 
gland, which in consequence may lead to tuberous 
goitre. Coexisting DM may also affect the efficacy of 
hypothyroid substitution treatment with levothyroxine 
[62, 63]. Unrecognised thyroid dysfunction may affect 
DM metabolic control. Interactions between thyroid 
hormones and mechanisms controlling appetite, energy 
expenditure, and insulin sensitivity are also important. 
A better understanding of this multi-faceted relation-
ship between DM and thyroid disease can help optimize 
Thyroid 
function
Glucose 
metabolism
Mechanism of action
1. Decrease in insulin half-life: 
— increased degradation rate
— increased release of biologically inactive 
insulin precursors
— a defect in the processing of proinsulin
 
2. Increasing the absorption of glucose  
in the intestines
 
3. Increasing endogenous glucose production: 
— increase in GLUT-2 concentration 
in the plasma membrane of hepatocytes
 (the main glucose transporter in the liver)
— increase in hepatic gluconeogenesis
 
4. Increase in lipolysis with an increase  
in FFA (catecholamine stimulated lipolysis)
5. Increasing the concentration of GH, 
glucagon and catecholamines
6. Lactate increase
Hyperthyroidism Hyperglycemia 
Figure 2. Effect of thyroid hormones on glucose metabolism. FFA — free fatty acids; GH — growth hormone
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the management of patients with DM [51]. Treatment 
of thyroid dysfunction in DM patients has a beneficial 
effect on glycaemic control, reduces cardiovascular risk, 
and improves patients’ overall well-being [64]. 
Thyroid dysfunction in patients 
with diabetic retinopathy
There are few reports in the literature regarding the 
impact of thyroid disease on the development and 
course of DR. The hypothalamic-pituitary-thyroid axis 
plays an important role in retinal development and 
contributes to the increase in retinal vascular density 
[65, 66]. Most research on this topic is based on animal 
models. During the morphometric analysis of rats in 
which hypothyroidism was induced, Pinazo-Durán et 
al. showed a decrease in eyeball volume and thinning 
of the retinal layers. Reduced transverse dimension 
and retardation of optic nerve myelination were also 
found in rats with hypothyroidism compared to the 
control group [67]. In rats with induced hypothyroid-
ism, Kocaturka et al. showed a lower level of sirtuin 2 
(SIRT-2) protein in the retinal ganglion cell layer, which 
indicates a significant influence of thyroid hormones 
on the normal development of retinal cytoarchitecture 
[68]. During studies on rats with DM and retinal micro-
angiopathy, recognised as thickening of the basement 
membrane of the capillaries, it was found that the 
concentration of T4 in rat plasma decreased after eight 
months, and the same of T3 after eight and 12 months, 
compared to the control group [69]. It was proven that 
rats with induced DM and T4 deficiency have altered 
vascular reactivity, which is reversible with T4 supple-
mentation [70]. Relationships in symptoms among 
patients with thyroid disease have also been demon-
strated in patients with DR. These are often factors that 
contribute to the pathogenesis of DR in patients with 
DM. What is interesting is the relationship between 
thyroid disease and retinal blood flow. Ittermann et al. 
observed in their study that in the group of patients 
with a higher TSH concentration, the arteriovenous 
index was lower and the retinal arterial vessels were 
narrower than in those with euthyroid disease. Arterial 
vasoconstriction can be caused by microvascular dam-
age secondary to local hypertension, atherosclerosis, 
and inflammation [71]. In DR, chronic inflammation 
occurs that causes damage to the vascular endothe-
lium. Czarnywojtek et al. showed that in patients 
with thyroid disease, both in hyperthyroidism and 
hypothyroidism, serum CRP levels increase. It can be 
assumed that thyroid dysfunction can lead to systemic 
inflammation [72]. Christa-Crain et al. and Kvetny et 
al. showed an interesting relationship in the study of 
patients with SCH, who had significantly higher CRP 
concentration in serum than people without SCH [55]. 
Iitaka et al. observed elevated serum VEGF levels in 
patients with untreated GD and HT, which positively 
correlated with the degree of thyroid vascularisation. 
VEGF C and Flt-4 were also localised in human tissues 
of goitre and AITD. Lymphocytic thyroiditis and dif-
ferentiated thyroid cancers are more strongly expressed 
by VEGF than healthy gland tissues [73, 74]. Increased 
Figure 3. Effect of thyroid hormones on glucose metabolism
1. Reduction of liver glucose levels  
 
2. Reducing the need for insulin  
 
3. Recurrent episodes of hypoglycemia
4. Emergence of insulin resistance and impaired 
insulin-stimulated glucose utilization in peripheral 
tissues (metabolic syndrome risk factor)
 
5. Decrease in cardiac output and increase
in peripheral vascular resistance resulting
in reduced renal ow and glomerular ltration rate, 
increasing the risk of nephropathy
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function
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metabolism
Mechanism of action
Hypothyroidism Hypoglycemia 
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levels of VEGF expression are already observed in the 
early stages of DR [29]. Patients with hypothyroidism 
have an IR, a condition in which there is an elevated 
concentration of plasminogen activator inhibitor-1 
(PAI-1), belonging to the group of fibrinolysis inhibi-
tors. Defective fibrinolysis or impaired IR-associated 
vasodilatation may be correlated with decreased vaso-
dilatability and secondary fibrosis, which leads to retinal 
vascular destruction and secondary revascularisation 
in DR [55]. Thyroid dysfunction significantly affects 
changes in lipid profile [75]. Dyslipidaemia was more 
frequent in patients with DR than in the control group 
[76]. Dyslipidaemia may affect the occurrence of DR 
in patients with thyroid dysfunction. In the pathogen-
esis of autoimmune thyroid disease and DR, oxidative 
stress appears to be an important risk factor that has 
a negative impact on the morphology and function-
ing of the retina. Higher activity of malondialdehyde 
(MDA) and lower activity of paraoxonase 1 (PON1) was 
demonstrated in the plasma of patients with hypothy-
roidism [77]. Looker et al. showed that higher serum 
homocysteine concentration is a risk factor for DR, and 
homocysteine may increase lipid peroxidation, which 
leads to increased levels of low-density oxidised lipo-
protein (oxLDL), accelerating the progression of vascu-
lar disease [55]. To date, little research has been done 
into the effects of thyroid disease on the development 
of DR in patients with type 1 DM. Literature analysis 
of the occurrence of DR in patients with type 1 DM, 
however, shows a significant impact of thyroid disease 
on the development of DR. Examining the population 
of patients with type 1 DM in Brazil, Rodacki et al. 
proved that TSH levels at 0.4–2.5 mU/L are associated 
with a lower risk of DR and renal failure in people with 
type 1 DM, regardless of glycaemia control and disease 
duration [78]. Quite unexpectedly, Rogowicz-Frontczak 
A. et al. showed in their study that patients with type 
1 DM and positive aTPO, aTg, or TRAb antibodies 
develop less microangiopathy compared to the group 
without AITD. They were the first to indicate that DR 
was less common among patients with type 1 DM and 
AITD [79]. Probably the genetic profile of patients with 
autoimmune polyglandular syndrome has a protective 
effect on the development of DR, despite the higher 
risk of overt thyroid disease and other organ-specific 
disorders [80]. The effect of thyroid preparations on 
DR was previously studied by Schneider et al. in 19 
patients with type 1 DM for two years. Twelve out of 
19 cases showed improvement in thyroid prepara-
tions with a reduction in haemorrhage and exudate, 
but these results have not been confirmed in a larger 
population [81]. There are few studies in the literature 
that have shown a link between hypothyroidism and 
DR in patients with type 2 DM. Sailesh S. et al. demon-
strated that patients with type 2 DM and concomitant 
hypothyroidism (during treatment with levothyroxine) 
are exposed to a significantly lower risk of developing 
DR. The exact mechanism of this effect is unknown and 
requires further investigation. In these patients, the 
protective effect against DR was found even though 
the patients were older and had higher systolic blood 
pressure than the control group [82]. Few observa-
tions relate to the occurrence of DR in the population 
of SCH patients with type 2 DM. A meta-analysis of 
all published epidemiological studies on DR and SCH 
conducted by Wu et al. showed that SCH was associ-
ated with DR, and exposure to SCH may increase the 
risk of developing DR by 2.13 fold [83]. This was also 
confirmed by recent studies by Borooah et al., who 
showed that a more severe form of DR was diagnosed in 
patients with SCH compared to patients with euthyroid 
disease. The severity of DR increases significantly with 
the increase of serum TSH concentration [84]. There-
fore, patients with SCH should undergo frequent eye 
examinations to rule out DR. To date, no reasons have 
been established for this phenomenon.Coexistence of 
DM with thyroid disease leads to endothelial damage. 
The degree of endothelial dysfunction has a significant 
impact on the course of macro- and microangiopathic 
complications in patients with DM. However, there is 
a lack of large-scale research on the impact of thyroid 
disorders on the occurrence and course of chronic 
complications of DM, including DR. Factors that have 
a protective effect on the occurrence of DR include good 
metabolic control of DM, early detection and treatment 
of hypertension and dyslipidaemia, maintenance of 
normal weight, and cessation of smoking [85]. Patients 
with DM have thyroid homeostasis disorders that de-
pend on the degree of metabolic control. However, im-
proving DM control does not appear to affect T4 levels 
or the hypothalamic–pituitary–thyroid axis, which may 
explain why some patients develop DR despite good 
control and vice versa. Disruption of thyroid hormone 
homeostasis may contribute to a higher incidence of 
DR in patients with hypothyroidism due to the fact 
they are not treated with levothyroxine preparations.
Conclusion
Our literature analysis draws attention to an important 
clinical problem, which is progressive vision loss in 
patients with DM and connections in the discussed 
area, among others the effect of thyroid disease and 
levothyroxine substitution on the development and 
course of DR in patients with DM. Having presented all 
the above facts, it is necessary to emphasise that early 
detection and monitoring of thyroid dysfunction in 
DM is extremely important and can contribute to stop 
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appearance the complications of DM patients. This may 
help prevent blindness and improve the quality of life 
for patients with DM. 
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